Active metabolites resulting from decarboxylation, reduction and ester hydrolysis of parent drugs

I. Hartyánszky, H. Kalász, E. Adeghate, Zs Gulyás, M. Y. Hasan, K. Tekes, A. Adem, P. Sótónyi

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Decarboxylation, reduction and hydrolysis can yield active metabolites from the parent drug. Major therapeutic indications and metabolic routes of these drugs are reviewed. Changes in the logP values (determined and calculated) from the parent drug to the active metabolite show certain characteristics in comparison to other phase I metabolic alterations. Metabolic decarboxylation of parent drug is commonly associated with increase in lipophilicity. However, in some cases, decarboxylation may cause a reduction in lipophilicity. Ester hydrolysis generally unmasks either the polar carboxylic or hydroxyl group with the outcome of an increase in hydrophilicity. On the contrary, hydrolysis of phosphate ester means a huge increase in the lipophilic character of the drug, as the highly polar phosphate group is removed.

Original languageEnglish
Pages (from-to)835-862
Number of pages28
JournalCurrent Drug Metabolism
Volume13
Issue number6
DOIs
Publication statusPublished - Jul 2012

Fingerprint

Decarboxylation
Metabolites
Hydrolysis
Esters
Pharmaceutical Preparations
Phosphates
Hydrophilicity
Hydrophobic and Hydrophilic Interactions
Hydroxyl Radical

Keywords

  • Active metabolites
  • Metabolic decarboxylation
  • Metabolic reduction and metabolic hydrolysis

ASJC Scopus subject areas

  • Pharmacology
  • Clinical Biochemistry

Cite this

Active metabolites resulting from decarboxylation, reduction and ester hydrolysis of parent drugs. / Hartyánszky, I.; Kalász, H.; Adeghate, E.; Gulyás, Zs; Hasan, M. Y.; Tekes, K.; Adem, A.; Sótónyi, P.

In: Current Drug Metabolism, Vol. 13, No. 6, 07.2012, p. 835-862.

Research output: Contribution to journalArticle

Hartyánszky, I. ; Kalász, H. ; Adeghate, E. ; Gulyás, Zs ; Hasan, M. Y. ; Tekes, K. ; Adem, A. ; Sótónyi, P. / Active metabolites resulting from decarboxylation, reduction and ester hydrolysis of parent drugs. In: Current Drug Metabolism. 2012 ; Vol. 13, No. 6. pp. 835-862.
@article{3661de808d964fda87367e76b95632a7,
title = "Active metabolites resulting from decarboxylation, reduction and ester hydrolysis of parent drugs",
abstract = "Decarboxylation, reduction and hydrolysis can yield active metabolites from the parent drug. Major therapeutic indications and metabolic routes of these drugs are reviewed. Changes in the logP values (determined and calculated) from the parent drug to the active metabolite show certain characteristics in comparison to other phase I metabolic alterations. Metabolic decarboxylation of parent drug is commonly associated with increase in lipophilicity. However, in some cases, decarboxylation may cause a reduction in lipophilicity. Ester hydrolysis generally unmasks either the polar carboxylic or hydroxyl group with the outcome of an increase in hydrophilicity. On the contrary, hydrolysis of phosphate ester means a huge increase in the lipophilic character of the drug, as the highly polar phosphate group is removed.",
keywords = "Active metabolites, Metabolic decarboxylation, Metabolic reduction and metabolic hydrolysis",
author = "I. Harty{\'a}nszky and H. Kal{\'a}sz and E. Adeghate and Zs Guly{\'a}s and Hasan, {M. Y.} and K. Tekes and A. Adem and P. S{\'o}t{\'o}nyi",
year = "2012",
month = "7",
doi = "10.2174/138920012800840437",
language = "English",
volume = "13",
pages = "835--862",
journal = "Current Drug Metabolism",
issn = "1389-2002",
publisher = "Bentham Science Publishers B.V.",
number = "6",

}

TY - JOUR

T1 - Active metabolites resulting from decarboxylation, reduction and ester hydrolysis of parent drugs

AU - Hartyánszky, I.

AU - Kalász, H.

AU - Adeghate, E.

AU - Gulyás, Zs

AU - Hasan, M. Y.

AU - Tekes, K.

AU - Adem, A.

AU - Sótónyi, P.

PY - 2012/7

Y1 - 2012/7

N2 - Decarboxylation, reduction and hydrolysis can yield active metabolites from the parent drug. Major therapeutic indications and metabolic routes of these drugs are reviewed. Changes in the logP values (determined and calculated) from the parent drug to the active metabolite show certain characteristics in comparison to other phase I metabolic alterations. Metabolic decarboxylation of parent drug is commonly associated with increase in lipophilicity. However, in some cases, decarboxylation may cause a reduction in lipophilicity. Ester hydrolysis generally unmasks either the polar carboxylic or hydroxyl group with the outcome of an increase in hydrophilicity. On the contrary, hydrolysis of phosphate ester means a huge increase in the lipophilic character of the drug, as the highly polar phosphate group is removed.

AB - Decarboxylation, reduction and hydrolysis can yield active metabolites from the parent drug. Major therapeutic indications and metabolic routes of these drugs are reviewed. Changes in the logP values (determined and calculated) from the parent drug to the active metabolite show certain characteristics in comparison to other phase I metabolic alterations. Metabolic decarboxylation of parent drug is commonly associated with increase in lipophilicity. However, in some cases, decarboxylation may cause a reduction in lipophilicity. Ester hydrolysis generally unmasks either the polar carboxylic or hydroxyl group with the outcome of an increase in hydrophilicity. On the contrary, hydrolysis of phosphate ester means a huge increase in the lipophilic character of the drug, as the highly polar phosphate group is removed.

KW - Active metabolites

KW - Metabolic decarboxylation

KW - Metabolic reduction and metabolic hydrolysis

UR - http://www.scopus.com/inward/record.url?scp=84863655870&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863655870&partnerID=8YFLogxK

U2 - 10.2174/138920012800840437

DO - 10.2174/138920012800840437

M3 - Article

VL - 13

SP - 835

EP - 862

JO - Current Drug Metabolism

JF - Current Drug Metabolism

SN - 1389-2002

IS - 6

ER -